Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Stanozolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stanozolol SCHEMBL6151066 | 1.00 | CYP2C19 (0.64) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| Stanozolol SCHEMBL12417517 | 1.00 | CYP2C19 (0.64) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| Stanozolol SCHEMBL19645424 | 1.00 | CYP2C19 (0.64) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| Oxymetholone SCHEMBL2024270 | 0.89 | ADORA3 (0.74) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| SCHEMBL27046793 | 0.89 | CYP2C19 (0.52) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| Stanozolol SCHEMBL13724751 | 0.86 | SHBG (0.61) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| SCHEMBL21392304 | 0.86 | CYP2C19 (0.49) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| Stanozolol SCHEMBL329926 | 0.85 | LMNA (0.63) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| SCHEMBL27046806 | 0.84 | CYP2C19 (0.45) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 | |
| SCHEMBL27046803 | 0.84 | CYP2C19 (0.45) | CYP2C19ADORA3ESR1CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7285 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| EP-4665501-A2 | CENTRIFUGAL MICRO-FLUIDIC DISK FOR DETECTING THE PRESENCE AND CONCENTRATION OF AN ANALYTE OF INTEREST | Lifeloc Technologies, Inc. (US) | 2025-12-24 | — | — | EP | claimed |
| EP-4630043-A1 | IMMUNE-ACTIVATING COMPLEXES | Dynamic Cell Therapies, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4630446-A1 | ENGINEERED SWITCHES FOR IMMUNE CELL ACTIVITY AND METHODS OF USE THEREOF | Dynamic Cell Therapies, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250295673-A1 | TREATMENT OF BREAST CANCER | LICHTEN EDWARD (US) | 2025-09-25 | — | — | US | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| US-12391924-B2 | Method for mesenchymal stem cell isolation and osteoblast differentiation | REGROW BIOSCIENCES PRIVATE LIMITED (IN) | 2025-08-19 | — | — | US | claimed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-0479867-A1 | COMPOSITIONS USEFUL AS CONTRACEPTIVES IN MALES. | COHEN MICHAEL (NL) | 1992-04-15 | — | — | EP | claimed |
| US-5071834-A | Purified activin B composition | GENENTECH, INC. (US) | 1991-12-10 | — | — | US | claimed |
| US-5026692-A | Prevention and treatment of immunodeficiency diseases | RESEARCH DEVELOPMENT CORPORATION OF JAPAN (JP) | 1991-06-25 | — | — | US | claimed |
| WO-1991000095-A1 | COMPOSITIONS USEFUL AS CONTRACEPTIVES IN MALES | COHEN MICHAEL (NL) | 1991-01-10 | — | — | WO | claimed |
| CN-1048327-A | Contraceptive composition for male | COHEN MICHAEL (NL) | 1991-01-09 | — | — | CN | claimed |
| EP-0142309-B1 | METHOD OF PREPARING STEROID COMPOUNDSHAVING A REDUCED PARTICLE SIZE FORM | STERWIN AG. (CH) | 1990-01-03 | — | — | EP | claimed |
| EP-0324037-A1 | Method of treatment of central nervous system diseases such as Alzheimer's disease and Parkinson's disease and method of diagnosing Alzheimer's disease | Aroonsakul, Chaovanee (US) | 1989-07-19 | — | — | EP | claimed |
| US-4717569-A | WATER SOLUBLE BINDER | STERLING DRUG INC. (US) | 1988-01-05 | — | — | US | claimed |
| EP-0142309-A2 | Method of preparing steroid compoundshaving a reduced particle size form | STERWIN AG. (CH) | 1985-05-22 | — | — | EP | claimed |
| US-4346709-A | Drug delivery devices comprising erodible polymer and erosion rate modifier | ALZA CORPORATION (US) | 1982-08-31 | — | — | US | claimed |